[144] ABBVIE INC. SEC Filing

Rhea-AI Filing Summary

AbbVie (ABBV) filed a Form 144 reporting proposed sales of common stock through Northern Trust Securities on the NYSE. The notice lists three proposed transactions: 61,500 shares (aggregate market value $12,043,268.25, approx. sale date 08/01/2025), 35,120 shares ($6,828,296.22, 08/04/2025) and 91,600 shares ($19,208,000, 08/04/2025). The filing shows a reported number of outstanding shares of 1,766,558,253.

The document discloses the acquisition history for the securities to be sold, showing they were received as restricted stock in grants dated between 02/28/2017 and 02/26/2021 with specific grant amounts listed. The filer indicates no securities sold in the past three months and includes the standard Rule 144 attestation about lack of undisclosed material adverse information.

Positive

• Filing provides full transaction detail: share counts, aggregate market values, broker (Northern Trust), exchange (NYSE) and approximate sale dates are disclosed
• Acquisition provenance disclosed: all securities to be sold are listed as acquired as restricted stock with grant dates between 2017 and 2021
• No recent sales reported in the past three months, as indicated by the filing

Negative

• Insider liquidity planned: proposed sales include tranches with aggregate market values listed up to $19,208,000
• Material amount disclosed: the three proposed tranches list aggregate values of $12,043,268.25, $6,828,296.22, and $19,208,000, which together represent sizeable individual transactions

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice disclosing planned insider sales totaling multiple tranches in August 2025; transparency is provided on grant origin.

The filing lists three proposed sales executed via Northern Trust on the NYSE: 61,500; 35,120; and 91,600 common shares, each with stated aggregate market values. The securities to be sold were acquired as restricted stock across 2017–2021, with specific grant sizes reported. No sales were reported in the prior three months. From a market-impact perspective, the document is a compliance disclosure rather than new operational information; it quantifies planned insider liquidity while confirming the shares originated from compensation grants.

Corporate Governance Expert

TL;DR: The Form 144 provides required transparency about an insider's planned share disposals and the restricted-stock origin of those holdings.

The form complies with Rule 144 disclosure by naming the broker (Northern Trust), listing exact share counts, aggregate market values, and approximate sale dates in August 2025. It also itemizes the acquisition dates and nature of the holdings (restricted stock), which helps assess vesting and compensation-related sales. The attestation that no undisclosed material adverse information is known is present, consistent with filing norms. Governance implications are informational rather than corrective.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Northern Trust Securities, Inc. 50 S. LaSalle Street, B-2 Chicago IL 60603	61500	12043268.25	1766558253	08/01/2025	NYSE
Common	Northern Trust Securities, Inc. 50 S. LaSalle Street, B-2 Chicago IL 60603	35120	6828296.22	1766558253	08/04/2025	NYSE
Common	Northern Trust Securities, Inc. 50 S. LaSalle Street, B-2 Chicago IL 60603	91600	19208000	1766558253	08/04/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/27/2019	Restricted Stock	Issuer			31977	02/27/2019	Compensation
Common	02/28/2020	Restricted Stock	Issuer			9523	02/28/2020	Compensation
Common	02/26/2021	Restricted Stock	Issuer			20000	02/26/2021	Compensation
Common	02/28/2017	Restricted Stock	Issuer			538	02/28/2017	Compensation
Common	02/27/2019	Restricted Stock	Issuer			34582	02/27/2019	Compensation
Common	02/28/2017	Restricted Stock	Issuer			91600	02/28/2017	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did ABBV file in this Form 144?

AbbVie filed a Form 144 reporting proposed sales of common shares via Northern Trust with three tranches listed for early August 2025.

How many ABBV shares are proposed for sale and what are the aggregate values?

Three proposed sales: 61,500 shares (aggregate value $12,043,268.25), 35,120 shares ($6,828,296.22), and 91,600 shares ($19,208,000).

Where will the ABBV shares be sold?

Broker and exchange: The filing names Northern Trust Securities, Inc. as broker and lists the NYSE as the exchange for the proposed sales.

What is the origin of the shares being sold?

Acquisition type: The filing states the securities were acquired as restricted stock in grants dated between 02/28/2017 and 02/26/2021 with specific amounts reported.

Has the filer sold ABBV securities in the past three months?

No: The Form 144 states "Nothing to Report" for securities sold during the past three months.